62 related articles for article (PubMed ID: 20178532)
1. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma.
Apostolidis L; Bergmann F; Jäger D; Winkler EC
Cancer Med; 2016 Sep; 5(9):2261-7. PubMed ID: 27456539
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma.
Chan SY; Gordon AN; Coleman RE; Hall JB; Berger MS; Sherman ML; Eten CB; Finkler NJ
Cancer Immunol Immunother; 2003 Apr; 52(4):243-8. PubMed ID: 12669249
[TBL] [Abstract][Full Text] [Related]
3. Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer.
Khanmammadov N; Dogan I; Okay NS; Khishigsuren B; Azizy A; Saip P; Gasimli K; Aydiner A
Minerva Obstet Gynecol; 2024 Jun; ():. PubMed ID: 38837188
[TBL] [Abstract][Full Text] [Related]
4. The synergism between Belotecan and cisplatin in gastric cancer.
Jung JY; Song SH; Kim TY; Park JH; Jong HS; Im SA; Kim TY; Bang YJ; Kim NK
Cancer Res Treat; 2006; 38(3):159-67. PubMed ID: 19771277
[TBL] [Abstract][Full Text] [Related]
5. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro.
Erickson-Miller CL; May RD; Tomaszewski J; Osborn B; Murphy MJ; Page JG; Parchment RE
Cancer Chemother Pharmacol; 1997; 39(5):467-72. PubMed ID: 9054963
[TBL] [Abstract][Full Text] [Related]
6. The DNA damage response: implications for tumor responses to radiation and chemotherapy.
Goldstein M; Kastan MB
Annu Rev Med; 2015; 66():129-43. PubMed ID: 25423595
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
Pizao PE; Smitskamp-Wilms E; Van Ark-Otte J; Beijnen JH; Peters GJ; Pinedo HM; Giaccone G
Biochem Pharmacol; 1994 Sep; 48(6):1145-54. PubMed ID: 7945408
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.
Kim GM; Kim YS; Ae Kang Y; Jeong JH; Kim SM; Hong YK; Sung JH; Lim ST; Kim JH; Kim SK; Cho BC
J Thorac Oncol; 2012 Apr; 7(4):731-6. PubMed ID: 22425922
[TBL] [Abstract][Full Text] [Related]
9. Initiation of DNA interstrand cross-link repair in mammalian cells.
Hlavin EM; Smeaton MB; Miller PS
Environ Mol Mutagen; 2010 Jul; 51(6):604-24. PubMed ID: 20658650
[TBL] [Abstract][Full Text] [Related]
10. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy.
Lee MW; Ryu H; Song IC; Yun HJ; Jo DY; Ko YB; Lee HJ
Medicine (Baltimore); 2020 Apr; 99(17):e19931. PubMed ID: 32332673
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
Li F; Jiang T; Li Q; Ling X
Am J Cancer Res; 2017; 7(12):2350-2394. PubMed ID: 29312794
[TBL] [Abstract][Full Text] [Related]
13. Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs.
Park YH; Chung CU; Park BM; Park MR; Park DI; Moon JY; Park HS; Kim JH; Jung SS; Kim JO; Kim SY; Lee JE
Can Respir J; 2016; 2016():3576201. PubMed ID: 28018128
[No Abstract] [Full Text] [Related]
14. Major clinical research advances in gynecologic cancer in 2010.
Suh DH; Kim JW; Kim K; Kang SB
J Gynecol Oncol; 2010 Dec; 21(4):209-18. PubMed ID: 21278881
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
[TBL] [Abstract][Full Text] [Related]
18. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
